Researchers from the University of British Columbia, in collaboration with the University of Wisconsin-Madison, have made significant strides in understanding the muscle pain associated with statin use. Their findings, published in Nature Communications, pave the way for the creation of safer statins that minimize these adverse effects.
Understanding Statin Interaction with Muscle Cells
To investigate the underlying mechanism, the team employed cryo-electron microscopy, a sophisticated imaging technique that reveals proteins at near-atomic resolution. This allowed them to observe the interaction between statins and a crucial muscle protein called the ryanodine receptor (RyR1).
The ryanodine receptor regulates calcium flow within muscle cells, functioning as a gate that opens during muscle contractions. The researchers discovered that when statins bind to RyR1, they inadvertently keep the channel open, leading to a continuous calcium leak. This leakage can be detrimental to muscle tissue, resulting in damage.
Dr. Steven Molinarolo, the lead author and postdoctoral researcher in UBC's biochemistry and molecular biology department, stated, "We were able to visualize, almost atom by atom, how statins attach to this channel. The calcium leak is responsible for muscle pain and, in severe cases, serious complications."
Revealing a Unique Binding Mechanism
The study primarily examined atorvastatin, one of the most widely prescribed statins globally. However, the researchers suggest that this mechanism may extend to other statins as well.
They found that statins bind to the ryanodine receptor in a distinctive manner. Three statin molecules cluster within a pocket of the protein. Initially, one molecule binds while the channel is closed, preparing it for activation. The subsequent two molecules then fit into place, fully opening the channel.
Dr. Filip Van Petegem, the senior author and professor at UBC's Life Sciences Institute, remarked, "This is the first clear depiction of how statins activate this channel. It represents a major advancement, offering a pathway for developing statins that do not impact muscle tissue."
Towards Safer Cholesterol-Lowering Medications
By focusing on modifying the parts of the statin molecule responsible for these adverse interactions, researchers aim to preserve the cholesterol-lowering effects while minimizing the risk of muscle damage.
While severe muscle injuries are rare among the over 200 million statin users worldwide, milder symptoms like soreness and fatigue are prevalent, often leading patients to discontinue their medication. These new insights could help alleviate such side effects, encouraging patients to adhere to treatments that safeguard their heart health.
Innovative Imaging Fuels Medical Advancements
This research underscores the transformative role of advanced imaging technologies in medical science. Utilizing the high-resolution macromolecular cryo-electron microscopy facility at UBC, the team captured the intricate statin-protein interaction, turning a long-standing safety concern into actionable scientific knowledge that could inform future therapies.
Dr. Van Petegem concluded, "Statins have been essential in cardiovascular treatment for many years. Our aim is to enhance their safety, allowing patients to benefit without the worry of serious side effects."
For the millions reliant on statins, these developments could lead to fewer muscle-related issues and an improved quality of life.